School of Public Health, Imperial College London, London, UK.
MRC Centre for Environment and Health, Imperial College London, London, UK.
Nat Commun. 2023 Aug 16;14(1):4957. doi: 10.1038/s41467-023-40643-w.
The value of SARS-CoV-2 lateral flow immunoassay (LFIA) tests for estimating individual disease risk is unclear. The REACT-2 study in England, UK, obtained self-administered SARS-CoV-2 LFIA test results from 361,801 adults in January-May 2021. Here, we link to routine data on subsequent hospitalisation (to September 2021), and death (to December 2021). Among those who had received one or more vaccines, a negative LFIA is associated with increased risk of hospitalisation with COVID-19 (HR: 2.73 [95% confidence interval: 1.15,6.48]), death (all-cause) (HR: 1.59, 95% CI:1.07, 2.37), and death with COVID-19 as underlying cause (20.6 [1.83,232]). For people designated at high risk from COVID-19, who had received one or more vaccines, there is an additional risk of all-cause mortality of 1.9 per 1000 for those testing antibody negative compared to positive. However, the LFIA does not provide substantial predictive information over and above that which is available from detailed sociodemographic and health-related variables. Nonetheless, this simple test provides a marker which could be a valuable addition to understanding population and individual-level risk.
SARS-CoV-2 侧向流动免疫分析（LFIA）测试用于估计个体疾病风险的价值尚不清楚。英国英格兰的 REACT-2 研究在 2021 年 1 月至 5 月期间从 361801 名成年人中获得了自我管理的 SARS-CoV-2 LFIA 测试结果。在这里，我们将其与后续住院（截至 2021 年 9 月）和死亡（截至 2021 年 12 月）的常规数据相关联。在那些接种过一种或多种疫苗的人中，LFIA 检测结果为阴性与 COVID-19 住院风险增加相关（HR：2.73 [95%置信区间：1.15，6.48]）、（所有原因）死亡（HR：1.59，95%CI：1.07，2.37）和 COVID-19 为根本原因的死亡（20.6 [1.83，232]）。对于 COVID-19 高危人群，已接种一种或多种疫苗的人，如果抗体检测结果为阴性，与阳性相比，所有原因死亡率每 1000 人增加 1.9 人。然而，LFIA 并没有提供比详细的社会人口统计学和与健康相关的变量所提供的信息更具预测性的信息。尽管如此，这种简单的测试提供了一个标志物，这可能是理解人群和个体风险的一个有价值的补充。
